{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:24:00Z","timestamp":1787664240768,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Beijing Kechuang Medical Development Foundation","award":["KC2021-JF-0167-17"],"award-info":[{"award-number":["KC2021-JF-0167-17"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s10147-026-03104-0","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T17:29:16Z","timestamp":1781803756000},"page":"1937-1950","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["RNF125 mediates the anti-breast cancer activity of betulinic acid through ubiquitin-dependent degradation of MYH9"],"prefix":"10.1007","volume":"31","author":[{"given":"Peng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binglu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9090-1667","authenticated-orcid":false,"given":"Li","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"key":"3104_CR1","doi-asserted-by":"publisher","unstructured":"Zannetti A (2023) Breast cancer: from pathophysiology to novel therapeutic approaches 2.0. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24032542","DOI":"10.3390\/ijms24032542"},{"issue":"6","key":"3104_CR2","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.drudis.2022.03.014","volume":"27","author":"S Yardim-Akaydin","year":"2022","unstructured":"Yardim-Akaydin S, Karahalil B, Baytas SN (2022) New therapy strategies in the management of breast cancer. Drug Discov Today 27(6):1755\u20131762. https:\/\/doi.org\/10.1016\/j.drudis.2022.03.014","journal-title":"Drug Discov Today"},{"key":"3104_CR3","doi-asserted-by":"publisher","unstructured":"Lau KH, Tan AM, Shi Y (2022) New and emerging targeted therapies for advanced breast cancer. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23042288","DOI":"10.3390\/ijms23042288"},{"key":"3104_CR4","doi-asserted-by":"publisher","unstructured":"Chunarkar-Patil P, Kaleem M, Mishra R, Ray S, Ahmad A, Verma D, Bhayye S, Dubey R, Singh HN, Kumar S (2024) Anticancer drug discovery based on natural products: from computational approaches to clinical studies. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines12010201","DOI":"10.3390\/biomedicines12010201"},{"key":"3104_CR5","doi-asserted-by":"publisher","first-page":"883857","DOI":"10.3389\/fphar.2022.883857","volume":"13","author":"JF Oliveira-Costa","year":"2022","unstructured":"Oliveira-Costa JF, Meira CS, Neves M, Dos Reis B, Soares MBP (2022) Anti-inflammatory activities of betulinic acid: a review. Front Pharmacol 13:883857. https:\/\/doi.org\/10.3389\/fphar.2022.883857","journal-title":"Front Pharmacol"},{"key":"3104_CR6","doi-asserted-by":"publisher","first-page":"104954","DOI":"10.1016\/j.antiviral.2020.104954","volume":"184","author":"MWC Loe","year":"2020","unstructured":"Loe MWC, Hao E, Chen M, Li C, Lee RCH, Zhu IXY, Teo ZY, Chin WX, Hou X, Deng J, Chu JJH (2020) Betulinic acid exhibits antiviral effects against dengue virus infection. Antiviral Res 184:104954. https:\/\/doi.org\/10.1016\/j.antiviral.2020.104954","journal-title":"Antiviral Res"},{"key":"3104_CR7","doi-asserted-by":"publisher","first-page":"111990","DOI":"10.1016\/j.biopha.2021.111990","volume":"142","author":"W Jiang","year":"2021","unstructured":"Jiang W, Li X, Dong S, Zhou W (2021) Betulinic acid in the treatment of tumour diseases: application and research progress. Biomed Pharmacother 142:111990. https:\/\/doi.org\/10.1016\/j.biopha.2021.111990","journal-title":"Biomed Pharmacother"},{"key":"3104_CR8","doi-asserted-by":"publisher","unstructured":"Fernandes S, Vieira M, Prud\u00eancio C, Ferraz R (2024) Betulinic acid for glioblastoma treatment: reality, challenges and perspectives. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms25042108","DOI":"10.3390\/ijms25042108"},{"issue":"6","key":"3104_CR9","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/s41419-018-0669-8","volume":"9","author":"Y Cai","year":"2018","unstructured":"Cai Y, Zheng Y, Gu J, Wang S, Wang N, Yang B, Zhang F, Wang D, Fu W, Wang Z (2018) Betulinic acid chemosensitizes breast cancer by triggering ER stress-mediated apoptosis by directly targeting GRP78. Cell Death Dis 9(6):636. https:\/\/doi.org\/10.1038\/s41419-018-0669-8","journal-title":"Cell Death Dis"},{"issue":"7","key":"3104_CR10","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1158\/1535-7163.Mct-12-0026","volume":"11","author":"X Liu","year":"2012","unstructured":"Liu X, Jutooru I, Lei P, Kim K, Lee SO, Brents LK, Prather PL, Safe S (2012) Betulinic acid targets YY1 and ErbB2 through cannabinoid receptor-dependent disruption of microRNA-27a:ZBTB10 in breast cancer. Mol Cancer Ther 11(7):1421\u20131431. https:\/\/doi.org\/10.1158\/1535-7163.Mct-12-0026","journal-title":"Mol Cancer Ther"},{"key":"3104_CR11","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.biopha.2016.10.018","volume":"84","author":"R Luo","year":"2016","unstructured":"Luo R, Fang D, Chu P, Wu H, Zhang Z, Tang Z (2016) Multiple molecular targets in breast cancer therapy by betulinic acid. Biomed Pharmacother 84:1321\u20131330. https:\/\/doi.org\/10.1016\/j.biopha.2016.10.018","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"3104_CR12","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/s41392-022-01152-2","volume":"7","author":"C Cai","year":"2022","unstructured":"Cai C, Tang YD, Zhai J, Zheng C (2022) The RING finger protein family in health and disease. Signal Transduct Target Ther 7(1):300. https:\/\/doi.org\/10.1038\/s41392-022-01152-2","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"3104_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1475-4924-2-21","volume":"2","author":"P Chu","year":"2003","unstructured":"Chu P, Pardo J, Zhao H, Li CC, Pali E, Shen MM, Qu K, Yu SX, Huang BC, Yu P, Masuda ES, Molineaux SM, Kolbinger F, Aversa G, de Vries J, Payan DG, Liao XC (2003) Systematic identification of regulatory proteins critical for T-cell activation. J Biol 2(3):21. https:\/\/doi.org\/10.1186\/1475-4924-2-21","journal-title":"J Biol"},{"issue":"1","key":"3104_CR14","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1042\/bj20070995","volume":"410","author":"AL Giannini","year":"2008","unstructured":"Giannini AL, Gao Y, Bijlmakers MJ (2008) T-cell regulator RNF125\/TRAC-1 belongs to a novel family of ubiquitin ligases with zinc fingers and a ubiquitin-binding domain. Biochem J 410(1):101\u2013111. https:\/\/doi.org\/10.1042\/bj20070995","journal-title":"Biochem J"},{"issue":"24","key":"3104_CR15","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1038\/s41388-023-02710-w","volume":"42","author":"Z Feng","year":"2023","unstructured":"Feng Z, Ke S, Wang C, Lu S, Xu Y, Yu H, Li Z, Yin B, Li X, Hua Y, Qian B, Bai M, Fu Y, Zhang Y, Wu Y, Ma Y (2023) RNF125 attenuates hepatocellular carcinoma progression by downregulating SRSF1-ERK pathway. Oncogene 42(24):2017\u20132030. https:\/\/doi.org\/10.1038\/s41388-023-02710-w","journal-title":"Oncogene"},{"key":"3104_CR16","doi-asserted-by":"publisher","unstructured":"Kodama T, Kodama M, Jenkins NA, Copeland NG, Chen HJ, Wei Z (2022) Ring finger protein 125 is an anti-proliferative tumor suppressor in hepatocellular carcinoma. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14112589","DOI":"10.3390\/cancers14112589"},{"issue":"9","key":"3104_CR17","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/j.celrep.2015.04.049","volume":"11","author":"H Kim","year":"2015","unstructured":"Kim H, Frederick DT, Levesque MP, Cooper ZA, Feng Y, Krepler C, Brill L, Samuels Y, Hayward NK, Perlina A, Piris A, Zhang T, Halaban R, Herlyn MM, Brown KM, Wargo JA, Dummer R, Flaherty KT, Ronai ZA (2015) Downregulation of the ubiquitin ligase RNF125 underlies resistance of melanoma cells to BRAF inhibitors via JAK1 deregulation. Cell Rep 11(9):1458\u20131473. https:\/\/doi.org\/10.1016\/j.celrep.2015.04.049","journal-title":"Cell Rep"},{"key":"3104_CR18","doi-asserted-by":"publisher","unstructured":"Yan Y, Kong X, Jin X, Bu J, Ni B, Rao Z, Guo J, Xu S (2025) RNA\u2013binding protein MBNL1 regulates tumor growth, chemosensitivity and antitumor immunity in lung adenocarcinoma by controlling the expression of tumor suppressor RNF125. Oncol Rep. https:\/\/doi.org\/10.3892\/or.2025.8907","DOI":"10.3892\/or.2025.8907"},{"key":"3104_CR19","doi-asserted-by":"publisher","unstructured":"Toma-Fukai S, Shimizu T (2021) Structural diversity of ubiquitin E3 ligase. Molecules. https:\/\/doi.org\/10.3390\/molecules26216682","DOI":"10.3390\/molecules26216682"},{"issue":"1","key":"3104_CR20","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12943-024-02046-3","volume":"23","author":"F Liu","year":"2024","unstructured":"Liu F, Chen J, Li K, Li H, Zhu Y, Zhai Y, Lu B, Fan Y, Liu Z, Chen X, Jia X, Dong Z, Liu K (2024) Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches. Mol Cancer 23(1):148. https:\/\/doi.org\/10.1186\/s12943-024-02046-3","journal-title":"Mol Cancer"},{"issue":"8","key":"3104_CR21","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.molmed.2023.05.006","volume":"29","author":"D Han","year":"2023","unstructured":"Han D, Wang L, Jiang S, Yang Q (2023) The ubiquitin-proteasome system in breast cancer. Trends Mol Med 29(8):599\u2013621. https:\/\/doi.org\/10.1016\/j.molmed.2023.05.006","journal-title":"Trends Mol Med"},{"key":"3104_CR22","doi-asserted-by":"publisher","first-page":"835603","DOI":"10.3389\/fonc.2022.835603","volume":"12","author":"M Wei","year":"2022","unstructured":"Wei M, Mo Y, Liu J, Zhai J, Li H, Xu Y, Peng Y, Tang Z, Wei T, Yang X, Huang L, Shao X, Li J, Zhou L, Zhong H, Wei C, Xie Q, Min M, Wu F (2022) Ubiquitin ligase RNF125 targets PD-L1 for ubiquitination and degradation. Front Oncol 12:835603. https:\/\/doi.org\/10.3389\/fonc.2022.835603","journal-title":"Front Oncol"},{"issue":"6","key":"3104_CR23","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s12033-022-00587-w","volume":"65","author":"C Jiang","year":"2023","unstructured":"Jiang C, He L, Xiao S, Wu W, Zhao Q, Liu F (2023) E3 ubiquitin ligase RNF125 suppresses immune escape in head and neck squamous cell carcinoma by regulating PD-L1 expression. Mol Biotechnol 65(6):891\u2013903. https:\/\/doi.org\/10.1007\/s12033-022-00587-w","journal-title":"Mol Biotechnol"},{"issue":"1","key":"3104_CR24","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1159\/000369691","volume":"35","author":"L Yang","year":"2015","unstructured":"Yang L, Zhou B, Li X, Lu Z, Li W, Huo X, Miao Z (2015) RNF125 is a ubiquitin-protein ligase that promotes p53 degradation. Cell Physiol Biochem 35(1):237\u2013245. https:\/\/doi.org\/10.1159\/000369691","journal-title":"Cell Physiol Biochem"},{"issue":"1","key":"3104_CR25","doi-asserted-by":"publisher","first-page":"5196","DOI":"10.1038\/s41467-021-25473-y","volume":"12","author":"K Wu","year":"2021","unstructured":"Wu K, Feng J, Lyu F, Xing F, Sharma S, Liu Y, Wu SY, Zhao D, Tyagi A, Deshpande RP, Pei X, Ruiz MG, Takahashi H, Tsuzuki S, Kimura T, Mo YY, Shiozawa Y, Singh R, Watabe K (2021) Exosomal miR-19a and IBSP cooperate to induce osteolytic bone metastasis of estrogen receptor-positive breast cancer. Nat Commun 12(1):5196. https:\/\/doi.org\/10.1038\/s41467-021-25473-y","journal-title":"Nat Commun"},{"key":"3104_CR26","doi-asserted-by":"publisher","unstructured":"Zhang Y, Zheng H, Xu M, Maeda N, Tsunedomi R, Kishi H, Nagano H, Kobayashi S (2023) Fyn-mediated paxillin tyrosine 31 phosphorylation regulates migration and invasion of breast cancer cells. Int J Mol Sci 24(21). https:\/\/doi.org\/10.3390\/ijms242115980","DOI":"10.3390\/ijms242115980"},{"issue":"14","key":"3104_CR27","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1038\/s41388-017-0114-y","volume":"37","author":"GH Lee","year":"2018","unstructured":"Lee GH, Yoo KC, An Y, Lee HJ, Lee M, Uddin N, Kim MJ, Kim IG, Suh Y, Lee SJ (2018) FYN promotes mesenchymal phenotypes of basal type breast cancer cells through STAT5\/NOTCH2 signaling node. Oncogene 37(14):1857\u20131868. https:\/\/doi.org\/10.1038\/s41388-017-0114-y","journal-title":"Oncogene"},{"issue":"9","key":"3104_CR28","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1007\/s12033-023-00877-x","volume":"66","author":"R Li","year":"2024","unstructured":"Li R, Li Y, Wang Z, Suo R, Ma R, Zhang J (2024) miR-181-5p\/KLHL5 promoted proliferation and migration of gastric cancer through activating METTL3-mediated m6A process. Mol Biotechnol 66(9):2415\u20132425. https:\/\/doi.org\/10.1007\/s12033-023-00877-x","journal-title":"Mol Biotechnol"},{"issue":"100","key":"3104_CR29","doi-asserted-by":"publisher","first-page":"37429","DOI":"10.18632\/oncotarget.26462","volume":"9","author":"RJ Schleifer","year":"2018","unstructured":"Schleifer RJ, Li S, Nechtman W, Miller E, Bai S, Sharma A, She JX (2018) KLHL5 knockdown increases cellular sensitivity to anticancer drugs. Oncotarget 9(100):37429\u201337438. https:\/\/doi.org\/10.18632\/oncotarget.26462","journal-title":"Oncotarget"},{"key":"3104_CR30","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.gene.2018.04.048","volume":"664","author":"A Pecci","year":"2018","unstructured":"Pecci A, Ma X, Savoia A, Adelstein RS (2018) MYH9: structure, functions and role of non-muscle myosin IIA in human disease. Gene 664:152\u2013167. https:\/\/doi.org\/10.1016\/j.gene.2018.04.048","journal-title":"Gene"},{"issue":"21","key":"3104_CR31","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1182\/blood.2019003064","volume":"135","author":"K Pal","year":"2020","unstructured":"Pal K, Nowak R, Billington N, Liu R, Ghosh A, Sellers JR, Fowler VM (2020) Megakaryocyte migration defects due to nonmuscle myosin IIA mutations underlie thrombocytopenia in MYH9-related disease. Blood 135(21):1887\u20131898. https:\/\/doi.org\/10.1182\/blood.2019003064","journal-title":"Blood"},{"key":"3104_CR32","doi-asserted-by":"publisher","first-page":"116118","DOI":"10.1016\/j.biopha.2023.116118","volume":"171","author":"Q Liu","year":"2024","unstructured":"Liu Q, Cheng C, Huang J, Yan W, Wen Y, Liu Z, Zhou B, Guo S, Fang W (2024) MYH9: a key protein involved in tumor progression and virus-related diseases. Biomed Pharmacother 171:116118. https:\/\/doi.org\/10.1016\/j.biopha.2023.116118","journal-title":"Biomed Pharmacother"},{"issue":"42","key":"3104_CR33","doi-asserted-by":"publisher","first-page":"34874","DOI":"10.1039\/d5ra03190g","volume":"15","author":"CT Selepe","year":"2025","unstructured":"Selepe CT, Dhlamini KS, Tshweu L, Kwezi L, Ramalapa B, Ray SS (2025) Advances and challenges in betulinic acid therapeutics and delivery systems for breast cancer prevention and treatment. RSC Adv 15(42):34874\u201334901. https:\/\/doi.org\/10.1039\/d5ra03190g","journal-title":"RSC Adv"},{"issue":"7","key":"3104_CR34","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1152\/physiolgenomics.00031.2016","volume":"48","author":"B Medvar","year":"2016","unstructured":"Medvar B, Raghuram V, Pisitkun T, Sarkar A, Knepper MA (2016) Comprehensive database of human E3 ubiquitin ligases: application to aquaporin-2 regulation. Physiol Genomics 48(7):502\u2013512. https:\/\/doi.org\/10.1152\/physiolgenomics.00031.2016","journal-title":"Physiol Genomics"},{"issue":"3","key":"3104_CR35","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/s41418-019-0400-z","volume":"27","author":"YL Yang","year":"2020","unstructured":"Yang YL, Zhang Y, Li DD, Zhang FL, Liu HY, Liao XH, Xie HY, Lu Q, Zhang L, Hong Q, Dong WJ, Li DQ, Shao ZM (2020) RNF144A functions as a tumor suppressor in breast cancer through ubiquitin ligase activity-dependent regulation of stability and oncogenic functions of HSPA2. Cell Death Differ 27(3):1105\u20131118. https:\/\/doi.org\/10.1038\/s41418-019-0400-z","journal-title":"Cell Death Differ"},{"issue":"1","key":"3104_CR36","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1186\/s13046-022-02576-y","volume":"41","author":"H Yang","year":"2022","unstructured":"Yang H, Xue M, Su P, Zhou Y, Li X, Li Z, Xia Y, Zhang C, Fu M, Zheng X, Luo G, Wei T, Wang X, Ding Y, Zhu J, Zhuang T (2022) RNF31 represses cell progression and immune evasion via YAP\/PD-L1 suppression in triple negative breast Cancer. J Exp Clin Cancer Res 41(1):364. https:\/\/doi.org\/10.1186\/s13046-022-02576-y","journal-title":"J Exp Clin Cancer Res"},{"issue":"7861","key":"3104_CR37","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41586-021-03566-4","volume":"594","author":"EG Otten","year":"2021","unstructured":"Otten EG, Werner E, Crespillo-Casado A, Boyle KB, Dharamdasani V, Pathe C, Santhanam B, Randow F (2021) Ubiquitylation of lipopolysaccharide by RNF213 during bacterial infection. Nature 594(7861):111\u2013116. https:\/\/doi.org\/10.1038\/s41586-021-03566-4","journal-title":"Nature"},{"issue":"7","key":"3104_CR38","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41594-018-0084-y","volume":"25","author":"V Akimov","year":"2018","unstructured":"Akimov V, Barrio-Hernandez I, Hansen SVF, Hallenborg P, Pedersen AK, Bekker-Jensen DB, Puglia M, Christensen SDK, Vanselow JT, Nielsen MM, Kratchmarova I, Kelstrup CD, Olsen JV, Blagoev B (2018) UbiSite approach for comprehensive mapping of lysine and N-terminal ubiquitination sites. Nat Struct Mol Biol 25(7):631\u2013640. https:\/\/doi.org\/10.1038\/s41594-018-0084-y","journal-title":"Nat Struct Mol Biol"},{"issue":"3","key":"3104_CR39","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/procel\/pwad045","volume":"15","author":"X Sheng","year":"2024","unstructured":"Sheng X, Xia Z, Yang H, Hu R (2024) The ubiquitin codes in cellular stress responses. Protein Cell 15(3):157\u2013190. https:\/\/doi.org\/10.1093\/procel\/pwad045","journal-title":"Protein Cell"},{"issue":"22","key":"3104_CR40","doi-asserted-by":"publisher","first-page":"3471","DOI":"10.1016\/j.jmb.2017.10.001","volume":"429","author":"MG Kattah","year":"2017","unstructured":"Kattah MG, Malynn BA, Ma A (2017) Ubiquitin-modifying enzymes and regulation of the inflammasome. J Mol Biol 429(22):3471\u20133485. https:\/\/doi.org\/10.1016\/j.jmb.2017.10.001","journal-title":"J Mol Biol"},{"issue":"3","key":"3104_CR41","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/ncb1833","volume":"11","author":"S Medjkane","year":"2009","unstructured":"Medjkane S, Perez-Sanchez C, Gaggioli C, Sahai E, Treisman R (2009) Myocardin-related transcription factors and SRF are required for cytoskeletal dynamics and experimental metastasis. Nat Cell Biol 11(3):257\u2013268. https:\/\/doi.org\/10.1038\/ncb1833","journal-title":"Nat Cell Biol"},{"issue":"1","key":"3104_CR42","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ymthe.2021.08.026","volume":"30","author":"Y Li","year":"2022","unstructured":"Li Y, Wang Z, Su P, Liang Y, Li Z, Zhang H, Song X, Han D, Wang X, Liu Y, Yang J, Chen B, Wang L, Zhao W, Yang Q (2022) circ-EIF6 encodes EIF6-224aa to promote TNBC progression via stabilizing MYH9 and activating the Wnt\/beta-catenin pathway. Mol Ther 30(1):415\u2013430. https:\/\/doi.org\/10.1016\/j.ymthe.2021.08.026","journal-title":"Mol Ther"},{"issue":"11","key":"3104_CR43","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/s41419-024-07164-w","volume":"15","author":"JX Song","year":"2024","unstructured":"Song JX, Wang Y, Hua ZP, Huang Y, Hu LF, Tian MR, Qiu L, Liu H, Zhang J (2024) FATS inhibits the Wnt pathway and induces apoptosis through degradation of MYH9 and enhances sensitivity to paclitaxel in breast cancer. Cell Death Dis 15(11):835. https:\/\/doi.org\/10.1038\/s41419-024-07164-w","journal-title":"Cell Death Dis"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03104-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03104-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03104-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:08:30Z","timestamp":1787663310000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03104-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3104"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03104-0","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"10 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This animal study was approved by the Ethics Committee of The Fourth Hospital of Hebei Medical University (approval number: 20240332). All experimental procedures were strictly performed in accordance with the Guide for the Care and Use of Laboratory Animals published by the National Academy of Sciences.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of The Fourth Hospital of Hebei Medical University (approval number: 2024KY104). All subjects provided informed consent for inclusion before participating in the study, and the tissue was used for future studies.","order":3,"name":"Ethics","label":"Clinical samples","group":{"name":"EthicsHeading","label":"Declarations"}}]}}